News | Antiplatelet and Anticoagulation Therapies | September 09, 2019

Prasugrel Cuts Ischemic Events in Acute Coronary Syndrome Patients

ISAR-REACT 5 trial presented in a Hot Line Session at ESC Congress 2019 together with WCC

Prasugrel Cuts Ischemic Events in Acute Coronary Syndrome Patients

September 9, 2019 — Prasugrel is superior to ticagrelor for reducing ischemic events in patients with acute coronary syndrome and a planned invasive strategy. The late-breaking results of the ISAR-REACT 5 trial were presented in a Hot Line Session at the European Society of Cardiology (ESC) Congress 2019, Aug. 31-Sept. 4 in Paris, France together with the World Congress of Cardiology and published in the New England Journal of Medicine.[1] There was no increase in the rate of major bleeding with prasugrel.

In acute coronary syndromes, a dual antiplatelet regimen with a P2Y12 receptor antagonist plus aspirin is the cornerstone of treatment. Prasugrel and ticagrelor provide greater, more rapid and consistent platelet inhibition compared to their predecessor clopidogrel. Both drugs are recommended over clopidogrel for 12 months after percutaneous coronary intervention (PCI) in acute coronary syndrome patients with and without ST-segment elevation (STEMI and NSTE-ACS, respectively)[2]. Until now, the relative merits of ticagrelor versus prasugrel for the one-year treatment of acute coronary syndrome patients were unknown.

The ISAR-REACT 5 trial[3] tested the hypothesis that ticagrelor is superior to prasugrel in reducing the primary composite endpoint of death, myocardial infarction or stroke within 12 months in acute coronary syndrome patients intended for an invasive strategy. A total of 4,018 patients were enrolled from 23 centers in Germany and Italy and randomly allocated to prasugrel or ticagrelor.

Patients assigned to ticagrelor received a loading dose as soon as possible after randomization. In other words, the timing of study drug administration was irrespective of clinical presentation and knowledge of coronary anatomy. In the prasugrel group, the timing of study drug initiation depended on clinical presentation. STEMI patients received prasugrel as soon as possible after randomization (i.e. they were pretreated). In patients with NSTE-ACS, administration of the prasugrel loading dose required knowledge of the coronary anatomy.

The primary composite endpoint of death, myocardial infarction or stroke at 12 months occurred in 9.3 percent of patients in the ticagrelor group and 6.9 percent in the prasugrel group (hazard ratio [HR] 1.36; 95 percent confidence interval [CI] 1.09–1.70; p = 0.006).

The incidence of the individual components of the primary endpoint in the ticagrelor and prasugrel groups was 4.5 percent versus 3.7 percent for death, 4.8 percent versus 3 percent for myocardial infarction, and 1.1 percent versus 1 percent for stroke. Definite or probable stent thrombosis occurred in 1.3 percent of patients assigned to ticagrelor and 1 percent assigned to prasugrel, and definite stent thrombosis in 1.1 percent versus 0.6 percent of patients, respectively.

The increase in anti-ischemic efficacy with prasugrel was not accompanied by a raised bleeding risk. Bleeding (BARC class 3 to 5) was observed in 5.4 percent of patients in the ticagrelor group and 4.8 percent of patients in the prasugrel group (HR 1.1; 95 percent CI 0.8–1.5; p = 0.46).

Principal investigator Prof. Stefanie Schuepke of the German Heart Centre Munich said, “In this investigator-initiated, multicentre, randomised clinical trial of invasively treated acute coronary syndrome patients, prasugrel significantly reduced the composite rate of death, myocardial infarction, or stroke compared to ticagrelor with no rise in the rate of major bleeding.”

For more information: www.escardio.org

References

1. Schüpke S., Neumann F-J., Menichelli M., et al. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine, published online Sept. 1, 2019. DOI: 10.1056/NEJMoa1908973

2. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40:87–165. doi:10.1093/eurheartj/ehy394.

3. ISAR-REACT: Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment.

Related Content

Ticagrelor Plus Aspirin Reduces Ischemic Events in Stable Coronary Patients With Diabetes
News | Antiplatelet and Anticoagulation Therapies | September 10, 2019
The combination of ticagrelor and aspirin reduces ischemic events compared with aspirin alone in patients with stable...
Advances in Anticoagulants Expand Options for VTE Prevention, Treatment
News | Antiplatelet and Anticoagulation Therapies | July 26, 2019
A new article published in AACN Advanced Critical Care outlines the traditional anticoagulant therapies familiar to...
Fragmin (dalteparin sodium) injection was cleared by the FDA for use in pediatric patients. It was initially approved by the FDA in 1994 for adults and is a type of heparin.

Fragmin (dalteparin sodium) injection is now cleared by the FDA for use in pediatric patients. It was initially approved by the FDA in 1994 for adults and is a type of heparin.

Technology | Antiplatelet and Anticoagulation Therapies | May 17, 2019
May 17, 2019 — The U.S.
PhaseBio Receives FDA Breakthrough Therapy Designation for Ticagrelor Reversal Agent
Technology | Antiplatelet and Anticoagulation Therapies | April 30, 2019
PhaseBio Pharmaceuticals Inc. announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy...
People With Heart Disease at Risk When Pharmacies Close
News | Antiplatelet and Anticoagulation Therapies | April 24, 2019
April 24, 2019 — New research from the University of Illinois at Chicago shows that when pharmacies close, people sto
Study Finds Only Six Percent of Patients Taking Statins as Directed
News | Antiplatelet and Anticoagulation Therapies | April 18, 2019
A recent study found patients with atherosclerotic cardiovascular disease cut their risk of a second major adverse...
HonorHealth Research Institute Launches SynIVUS-DAPT Study
News | Antiplatelet and Anticoagulation Therapies | April 16, 2019
HonorHealth Research Institute announced the first patients have been enrolled in the SynIVUS-DAPT Study. The clinical...
Lack of Physician Guidance, Fear of Side Effects Influence Statin Compliance
News | Antiplatelet and Anticoagulation Therapies | April 15, 2019
Despite national guidelines indicating statins can lower risk of heart attack and stroke, many patients who could...
Stopping DAPT After One Month Improved Outcomes in Stent Patients
News | Antiplatelet and Anticoagulation Therapies | March 25, 2019
Patients who stopped taking aspirin one month after receiving a stent in the heart’s arteries but continued taking the...
Apixaban Effective in Specific Cohort of Non-Valvular Atrial Fibrillation Patients
News | Antiplatelet and Anticoagulation Therapies | March 19, 2019
The Bristol-Myers Squibb-Pfizer Alliance announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis (apixaban...
Overlay Init